Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.
Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.
The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 21, 23 | 0.00 Increased by +100.00% | -0.80 Increased by +100.00% |
| Jul 10, 23 | 0.00 Increased by +100.00% | -0.75 Increased by +100.00% |
| Apr 18, 23 | -0.58 Decreased by -141.67% | -0.28 Decreased by -107.14% |
| Dec 22, 22 | -0.44 Increased by +6.38% | -0.23 Decreased by -91.30% |
| Sep 9, 22 | -0.47 Increased by +4.08% | -0.34 Decreased by -38.24% |
| Apr 14, 22 | -0.24 Increased by +45.45% | -0.26 Increased by +7.69% |
| Dec 31, 21 | -0.24 Increased by +53.85% | -0.26 Increased by +7.69% |
| Dec 30, 21 | -0.47 Increased by +2.08% | -0.37 Decreased by -27.03% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 438.00 K Increased by +29.59% | -4.15 M Increased by +55.08% | Decreased by -948.17% Increased by +65.33% |
| Dec 31, 23 | 437.50 K Increased by +29.63% | -6.36 M Increased by +14.00% | Decreased by -1.45 K% Increased by +33.65% |
| Sep 30, 23 | 438.00 K Increased by +N/A% | -4.15 M Decreased by N/A% | Decreased by -948.17% - |
| Mar 31, 23 | 437.50 K Increased by +29.44% | -6.36 M Increased by +40.72% | Decreased by -1.45 K% Increased by +54.20% |
| Dec 31, 22 | 338.00 K Increased by 0.00% | -9.24 M Increased by +13.83% | Decreased by -2.74 K% Increased by +13.83% |
| Sep 30, 22 | 337.50 K Increased by +0.15% | -7.39 M Increased by +63.29% | Decreased by -2.19 K% Increased by +63.34% |
| Jun 30, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Mar 31, 22 | 338.00 K Increased by +87.78% | -10.73 M Increased by +39.03% | Decreased by -3.17 K% Increased by +67.53% |